Contract Win
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your IXI notes
IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, is pleased to announce that it has been contracted by a US based pharma client to provide its imaging biomarker services for a Phase 1/2 clinical trial for patients with Huntington's Disease (HD). The trial is expected to run for up to ten years and contribute close to £2m to the Company's order book.
Giulio Cerroni, Chief Executive Officer of IXICO, commented:
"IXICO's expertise in providing advanced imaging biomarkers and radiological reads for HD is widely recognised. We are delighted to be awarded this new contract and look forward to support our client's efforts in this important HD development programme."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.